𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Phase I study of tauromustine administered in a weekly schedule

✍ Scribed by Gjedde, Susanne B.; Mouridsen, Henning T.; L-Madsen, Ebbe; Jensen, Niels V.; Blomquist, Erik; Bergh, Jonas; Söderberg, Martin; Wählby, Svante


Book ID
123088024
Publisher
Elsevier Science
Year
1993
Tongue
English
Weight
245 KB
Volume
29
Category
Article
ISSN
0959-8049

No coin nor oath required. For personal study only.


📜 SIMILAR VOLUMES


Phase I study of oral menogaril administ
✍ David J. Stewart; Shailendra Verma; Jean A. Maroun; Lucille Robillard; Robert H. 📂 Article 📅 1990 🏛 Springer US 🌐 English ⚖ 741 KB

Forty-seven patients with solid tumors were treated on a phase I study of menogaril administered by mouth once per week. Nausea and vomiting were excessive at weekly doses of 350 and 450 mg/m2/week but were tolerable and controlled reasonably well by antiemetics at lower doses. There appeared to be

Assessment of N-methylformamide (NMF) ad
✍ Eric K. Rowinsky; Louise B. Grochow; Alexander Hantel; David S. Ettinger; Barbar 📂 Article 📅 1989 🏛 Springer US 🌐 English ⚖ 717 KB

This phase I study was conducted to reevaluate the dose-limiting toxicities, maximum tolerated (MTD) and recommended phase II doses of oral NMF administered on a three times weekly schedule for 4 out of every 6 weeks. This schedule was based on the observation that prolonged administration of NMF wa

A phase i-ii study of maytansine utilizi
✍ Roman Franklin; Michael K. Samson; Roberto J. Fraile; Hakam Abu-Zahra; Robert O' 📂 Article 📅 1980 🏛 John Wiley and Sons 🌐 English ⚖ 428 KB 👁 2 views

Maytansine, a new ansa macrolide antitumor antibiotic, was administered to a total of 107 patients in a Phase 1-11 study. Dose-limiting toxic reactions which occurred at 0.75-1.0 mg/M' in both Phase I and I1 were neurologic and consisted primarily of lethargylweakness (a debilitation syndrome) and p